Read more

November 16, 2022
1 min read
Save

Top in endocrinology: Gender-affirming hormone therapy; Cushing’s syndrome treatment

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In a recent study, 98% of transgender adolescents who were prescribed gender-affirming hormone treatment after using pubertal blockers continued to use gender-affirming hormones in adulthood.

“Puberty blockers play an important role in postponing puberty in adolescents with gender identity issues,” Marianne van der Loos, MD, a researcher in endocrinology at Amsterdam University Medical Centers, told Healio. “Our study showed that almost all youngsters who started with sex hormone treatment after a period of using puberty blockers and psychological care continue to use them.”

LGBTQ flag in woman's pants pocket
In a recent study, 98% of transgender adolescents who were prescribed gender-affirming hormone treatment after using pubertal blockers continued to use gender-affirming hormones in adulthood. Source: Adobe Stock

It was the top story in endocrinology last week.

The second top story was about the efficacy of Recorlev (levoketoconazole, Xeris Biopharma) in adults with Cushing’s syndrome. New data showed that the drug reduces mean urinary free cortisol levels for at least 12 months.

Read these and more top stories in endocrinology below:

Most transgender adolescents continue to use gender-affirming hormones in adulthood

Most transgender adolescents who used pubertal blockers and were later prescribed gender-affirming hormone therapy in the Netherlands continued to use hormones as adults, according to data published in The Lancet Child & Adolescent Health. Read more.

Cushing’s syndrome treatment maintains reductions in urinary free cortisol for 12 months

Most adults with Cushing’s syndrome receiving levoketoconazole twice daily maintained reductions in mean urinary free cortisol levels during a 12-month maintenance period, according to findings from the SONICS study extended evaluation. Read more.

Caloric restriction interventions may need to be adjusted for older adults with obesity

Weight loss through caloric restriction can improve cardiometabolic risk, chronic conditions and physical function for older adults with obesity, but certain factors should be considered when designing an intervention. Read more.

Diabetes incidence higher among young people with vs. without Down syndrome

Children, adolescents and young adults with Down syndrome have higher incidence rates of type 1 and type 2 diabetes compared with matched controls without Down syndrome, according to a study published in Diabetes Care. Read more.

Virtual visits confer similar weight loss to in-person visits for adults with obesity

Adults with obesity who attended virtual pharmacotherapy visits had a similar weight loss compared with those who attended in-person visits, data show. Read more.